Abiopharma

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm